Abstract
To the Editor. —We read with interest the report by Drs. Tabbara, Nozik, and O'Connor in theArchives(92:244-247, 1974) on the efficacy of clindamycin in the treatment of experimentally induced ocular toxoplasmosis. The search for a less toxic means of treating ocular toxoplasmosis is indeed important. With respect to the possible ocular toxicity of clindamycin in patients, our experience at the Retinal Service of the New York Hospital with clindamycin as a prophylactic agent to prevent infections resulting from a scleral buckling procedure may be of value. For the past year, it has been our practice to soak our silicone sponge explants in clindamycin prior to their placement. In addition, 0.75 ml of clindamycin (150 mg/ml) is injected below the Tenon capsule at the conclusion of the procedure. During the period in which we have been using clindamycin, we have noted no adverse effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
